Antagonists of leukotriene receptors in treatment of patients with bronchial asthma

1. Глобальная стратегия лечения и профилактики бронхиальной астмы М.: Атмосфера; 2002.

2. Global strategy for asthma diagnosis and management. The updated 2006 repot is available on www.ginasthma.org.

3. Rabe K.F., Pizzichini E., Stallberg B. Single inhaler therapy with budesonide / formoterol provides superior asthma control compared with fixed dosing with budesonide plus terbutaline as needed. J. Allergy Clin. Immunol. 2004; 113: 116.

4. Lane S.J. Leucotriene antagonists in asthma and rhinitis. Respir. Med. 1998; 92: 795–809.

5. Malmstrom K., Rodriguez)Gomez G., Guerra J. et al. Oral Montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann. Intern. Med. 1999; 130: 487–495.

6. Чучалин А.Г. (ред.). Качество жизни у больных бронхиальной астмой и хронической обструктивной болезнью легких. М.: Атмосфера; 2004.

7. Van Staa T.P., Cooper C., Leufkens H.G. The use of inhaled corticosteroids in the United Kingdom and the Netherlands. Respir. Med. 2003; 97 (5): 578–585.

8. Van der Palen J. Klein J.J., Rovers M.M. Compliance with inhaled medication and self-treatment guidelines following self-management programme in adult asthmatics. Eur. Respir J. 1997; 10: 652–657.

9. Jones P.W. Testing health status ("quality of life") questionnaires for asthma and COPD. Eur. Respir. J. 1998; 11(1): 5–6.

10. Sawyer S.M., Fardy H.J. Bridging the gap between doctors' and patients' expectations of asthma management. J. Asthma 2003; 40 (2): 131–138.

11. Holgate S.T. What is the place of leukotriene receptor antagonist in clinical practice? Eur. Respir. Rev. 2001; 11 (79): 41–46.

12. Buist A.S. Development of evidence based guidelines for inhaled therapeutic interventions in asthma. Eur. Respir. Rev. 1998; 58: 322–323.

13. Wenzel S. New approaches to anti-inflammatory therapy for asthma. Am. J. Med. 1998; 104 (3): 287–300.

14. Boulet L.P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113 (3): 587–592.

15. Finkelstein J.A., Lozano P., Farber H.J. Underuse of controller medications among Medicaid-insured children with asthma. Arch. Pediatr. Adolesc. Med. 2002; 156 (6): 562–567.

16. Белевский А.С. Образовательные программы для больных бронхиальной астмой. Пульмонология 1999; прил.: Бронхиальная астма. Руководство для врачей России (формулярная система): 28–33.

17. Barnes N.C., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 1998; 157: 1–53.

18. Krawiec M.E., Wenzel. S.E. Use of leucotriene antagonists in childhood asthma. Curr. Opin. Pediatr. 1999; 11: 540–547.

19. Dixon R.A., Diehl R.E., Opas E. Requirement of a 5-lipoxygenase-activating protein for leukotriene sunthesis. Nature 1990; 343: 282–284.

20. Dahel S.E., Rodger I., Botting J.L., eds. Leucotrienes. New concepts and tagets for therapy. London: William Harvey Press; 1998.

21. Smith L.J. Newer asthma therapies. Ann. Intern. Med. 1999; 130: 531–532.

22. Stevenson D.D., Simon R.A., Mathison D.A., Christiansen S.C. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann. Allerg. 2000; 85: 477–482.

23. Dahlen B., Nizankowska E., Szczeklik A. et al. Benefits from adding the 5-lipoxygenase inhibitor Zileuton to conventional therapy in aspirin-intolerant asthma. Am. J. Respir. Crit. Care Med. 1998; 4: 1187–1194.

24. Barnes N.C., Miller C.J. Effect of Leucotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of Zafirlukast trials. Thorax 2000; 55: 478–483.

25. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the Leucotriene pathway. N. Engl. J. Med. 1999; 340: 197.

26. Lipworth B.J. Leucotriene-receptor antagonists. Lancet 1999; 353: 57–62.

27. Busse W.W., Chervinsky P., Condemi J. et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J. Allergy. Clin. Immunol. 1998; 101: 457–463.

28. Lofdahl C.G., Reiss T.F., Leff J. et al. Randomised, placebo controlled trial of effect of Leucotriene receptor antagonist, Montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br. Med. J. 1999; 319: 87–90.

29. Virhow J.C., Prasse A., Naya I. et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 2000; 162: 578–585.

30. Kalyoncu A., Karakaya G., Sahin A. Experience of 10 years with Churg-Strauss syndrome: An accompaniment to or a transition from aspirin-induced asthma? Allergol. Immunopathol. 2002; 29 (5): 185–190.

31. Wechsler D., Finn D., Gunawardena R. et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117: 708–713.

32. Franco J. Pulmonary eosinophilia associated with Montelukast. Thorax 1999; 54 (6): 558–560.

33. Hosker H.S., Tuggey J.M. Montelukast and Churg-Strauss syndrome. Thorax 2001; 56 (3): 244.

34. Keogh K.A. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and Leucotriene receptor antagonists. Am. J. Med. 2003; 115 (4): 284–290.

35. Fish J.E., Kemp J.P., Lockey R.F. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study. Clin. Ther. 1997; 19: 675–690.

36. Nathan R.A., Bernstein J.A., Bielory L. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J. Allergy Clin. Immunol. 1998; 102: 935–942.

37. Suissa S., Dennis R., Ernst P. Effectiveness of the Leucotriene receptor antagonist Zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1997; 126: 177–183.

38. Ducharme F. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. The Cochrane Library 2001; Issue 4.

39. Ducharme F.M. Inhaled glucocorticoids versus Leucotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. J. 2003; 326 (7390): 621.

40. Ducharme F.M., Hicks G.C. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. (Cochrane Review). Cochrane Library 2004; Issue 1.

41. Chervinsky P.S., Friedman B., van Bavel J. et al. Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol. 2002; 110 (6): 847–854.

42. Baumgartner R.A., Martinez G., Edelman J.M. et al. Montelukast Asthma Study Group. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur. Respir. J. 2003; 21 (1): 123–128.

43. Riccioni G., Vecchia R.D., D'Orazio N. et al. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm. Pharmacol. Ther. 2003; 16 (2): 111–114.

44. Vaquerizo M.J. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58(3): 204–210.

45. Israel E., Rubin P., Kemp J.P. The effects of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann. Intern. Med. 1993; 119: 1059.

46. Чучалин А.Г., Астафьева Н.Г., Княжеская Н.П. и др. Диагностика и лечение аспириновой астмы. В кн.: Чучалин А.Г.(ред.). Клинические рекомендации. Бронхиальная астма у взрослых. Атопический дерматит. М.: Атмосфера; 2002. 209–229.

47. Price D.B., Hernandez D., Magyar P. et al. Adding Montelukast is at least as efficacious as doubling the Budesonide dose in persistent asthma. Am. J. Respir. Crit. Care Med. 2002; 165 (8): 211–216.

48. Simons F.E.R., Villa J.R., Lee B.W. et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J. Pediatr. 2001; 138: 694–698.

49. Laviolette M., Malmstrom K., Lu S. et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 1862–1868.

50. Tamaoki J., Kondo M., Sakai N. et al. Leucotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155: 1235–1240.

51. Laitinen L.A., Zetterstrom O., Holgate S.T. et al. Effects of Accolate in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroids optimised between 800 and 2 000 mcg per day. Allergy 1995; 50 (suppl. 26): 320.

52. O'Sullivan S., Akveld M., Burke C.M., Poulter L.W. Am. J. Respir. Crit. Care Med. 2003; 167 (5): 745–750.

53. Ducharme F. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br. Med. J. 2002; 324: 1545.

54. Lipworth B.J., Dempsey O.J., Aziz I. Effects of adding a leukotriene antagonist or a long-acting beta 2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. Am. J. Med. 2001; 109: 114–121.

55. McIvor R.A., Pizzichini E., Turner M.O. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 924–930.

56. Solans R., Bosch J.A., Selva A. et al. Related Articles, Links Montelukast and Churg-Strauss syndrome. Thorax 2002; 57 (2): 183–185.

57. Kemp J.P. Related Articles, Links Role of leukotriene receptor antagonists in pediatric asthma. Pediatr. Pulmonol. 2000; 30 (2): 177–182.

58. Louis R. Medication of the month. Montelukast (Singulair). Rev. Med. Liege 2001; 56(6): 460–462.

59. Ringdal N., Pruzinec R., Weber H.H. et al. Related Articles, Links The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. International Study Group. Respir Med. 2003; 97 (3): 234–241.

60. Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. Related evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroid. Chest 2001; 119 (4): 1021–1026.

61. Weber R.W., Hoffman M., Reine D.A., Nelson H.S. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes and preservatives in a population of perennial asthmatics. J. Allergy Clin. Immunol. 1990; 85: 59.

62. Lane S.J. Leucotriene antagonists in asthma and rhinitis. Respir. Med. 1998; 92: 795–809.

63. Mastalerz L., Nizankowska E., Sanak M. et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a Leucotriene receptor antagonist. Eur. J. Clin. Invest. Relat. Articl. 2002; 32 (12): 949–955.

64. Paganin F., Poubeau P., Yvin J.L. The effectiveness of Leucotriene antagonists in the treatment of aspirin-intolerant asthmatic patient. Presse Med. 2003; 14: 978–984.

65. Mastalerz L., Gawlewicz)Mroczka A., Nizankowska E. et al. Protection against exercise-induced bronchoconstriction by Montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin. Exp. Allergy 2002; 32 (9): 1360–1365.

66. Stevenson D.D., Simon R.A., Mathison D.A. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann. Allergy Asthma Immunol. 2000; 85: 477–482.

67. Volkman J.A., Pontikes P.J. Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics. Ann. Pharmacother. 2002; 36 (9): 1457–1461.

68. Новикова Н.Д., Лещенко И.В. Эффективность монтелукаста при 6-месячной терапии больных бронхиальной астмой. Атмосфера: Пульмонол. и аллергол. 2003; 4: 54–56.

69. Novikova N.D., Leshchenko I.V. Application Моntelukast at patients with a mild persistent bronchial asthma. Pulmonology 2004; suppl.: 777.

70. Novikova N.D., Leshchenko I.V. Application Моntelukast at patients with moderate persistent bronchial asthma. Pulmonology 2004; suppl.: 778.